Velpatasvir

Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

Retrieved on: 
Wednesday, October 25, 2023
Liver, Neoplasm, HCC, Mouse, Health, Conditional sentence, Virus, Sofosbuvir, Artificial intelligence, Scripps Research, Growth, Liver cancer, HCV, Fatty liver disease, DRS, Velpatasvir, HEPA, Cancer, Pharmaceutical industry, Medical imaging, Dietary supplement

The study was published in the peer-reviewed, open access scientific journal, Viruses, and was conducted by Drs.

Key Points: 
  • The study was published in the peer-reviewed, open access scientific journal, Viruses, and was conducted by Drs.
  • Winston Stauffer, Philippe Gallay, and colleagues at The Scripps Research Institute (La Jolla, California).
  • Sofosbuvir, velpatasvir and rencofilstat treatments initiated at week 16 all eliminated HCV infection.
  • Not only could rencofilstat have an enormous impact on human health, but the investment growth opportunities associated with treating these high-need, global-scale diseases are equally large.”
    Hepion recently announced a new mechanism by which rencofilstat exerts anti-cancer activity in liver cancer and the drug’s anti-cancer activity in numerous cell lines representing 86% of cancer types.

U.S. Food and Drug Administration Approves New Formulation of Epclusa®, Expanding Pediatric Indication to Treat Children Ages 3 and Older With Chronic Hepatitis C

Retrieved on: 
Thursday, June 10, 2021
Health, FDA, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Drugs, Gilead Sciences, Health sciences, Chemistry, Combination drugs, Breakthrough therapy, Specialty drugs, Hepatitis C, Sofosbuvir, Velpatasvir, Protease inhibitor, Viral hepatitis

The recommended dosage of Epclusa in children ages 3 years and older is based on weight.

Key Points: 
  • The recommended dosage of Epclusa in children ages 3 years and older is based on weight.
  • Sofosbuvir/velpatasvir is the only protease inhibitor-free, pangenotypic HCV regimen approved for patients as young as 3 years of age.
  • Of the seven patients who did not achieve cure, all discontinued treatment within one to 20 days of starting treatment.
  • The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.

Cocrystal Pharma Presents Positive Data from U.S. Phase 2a Study of CC-31244 Demonstrating Ability to Identify Patients More Likely to Respond to Ultrashort Treatment of HCV

Retrieved on: 
Monday, November 11, 2019
Drugs, Gilead Sciences, Chemical compounds, Organic compounds, RTT, Breakthrough therapy, Combination drugs, Sofosbuvir, Velpatasvir, Hepatitis C

Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultrashort treatment of HCV infected individuals.

Key Points: 
  • Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultrashort treatment of HCV infected individuals.
  • Phase 2a trial, on Sunday November 10, 2019 and is available on the Companys website here .
  • Phase 2a study that were presented this past weekend at the AASLD 2019 Liver Meeting.
  • Phase 2a study is an open-label study designed to evaluate the safety, tolerability, and preliminary efficacy of CC-31244 with Epclusa in 12 subjects with treatment-nave HCV genotype 1.

Cocrystal Pharma Announces New Data on CC-31244 and Abstract Acceptance for Poster Presentation at the AASLD 2019 Liver Meeting

Retrieved on: 
Wednesday, October 30, 2019
Medicine, Medical specialties, RTT, Drugs, Gilead Sciences, Healthcare-associated infections, Breakthrough therapy, American Association for the Study of Liver Diseases, Hepatitis C, Sofosbuvir, Velpatasvir, Liver disease

Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultra-short treatment of HCV infected individuals was selected for presentation at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting being held November 8-12, 2019 in Boston, MA.

Key Points: 
  • Phase 2a study evaluating CC-31244 and sofosbuvir/velpatasvir (Epclusa) for the ultra-short treatment of HCV infected individuals was selected for presentation at the American Association for the Study of Liver Diseases (AASLD) 2019 Liver Meeting being held November 8-12, 2019 in Boston, MA.
  • We are pleased to be presenting this positive data at the AASLD 2019 meeting.
  • Poster 1673
    For additional information about theU.S.Phase 2a study of CC-31244 for the treatment of viral hepatitis C, please visit ClinicalTrials.gov and reference identifierNCT03501550.
  • AASLD is the leading organization of scientists and health care professionals committed to preventing and curing liver disease.